

REMARKS/ARGUMENTS

Reconsideration is respectfully requested.

No amendment is made to the claims.


Provided herewith is a Supplemental Response to the response filed on October 26, 2009. In this Supplemental Response is provided a Declaration from Xu Qishou. The Declarant helped to structure tests to assess riboflavin derivatives, including three sets of tests conducted to assess the effects of: (1) in vitro hydrolysis of riboflavin derivatives; (2) conducting an oral administration of riboflavin derivatives; and (3) conducting an intramuscular injection administration of riboflavin derivatives. (See Qishou Declaration ("Decl.") ¶5.) The Declaration provides clear evidence of the "...unexpected results of using 5'-lauric acid as opposed to those known in the art, especially di-, tri-, and tetra-ester of riboflavin." (See Qishou Decl. ¶7.) The results conclusively show that riboflavin-5'-laurate, as claimed in the present invention, have the "...best long-acting nutritional effects compared with others, that may be resulted in by the combination of its specific esterification degree, esterification site and ester-forming carboxylic acid." (See Qishou Decl., Results p.5 last ¶.)

The Applicant submits that this Supplemental Response provides evidence of the unexpected long-acting properties of the compound made by the methods of the present invention. The Applicant reiterates the position in the response filed October 26, 2009, and respectfully requests that the Examiner withdraw this rejection as to the claims.

The Applicant requests favorable consideration.

Respectfully submitted,

Dated: 1-12-2010



Zareefa B. Flener, Reg. No. 52,896
Ladas & Parry LLP
224 South Michigan Avenue
Chicago, Illinois 60604
(312) 427-1300